ATS Medical semi-rigid valve repair device cleared by FDA
This article was originally published in The Gray Sheet
Executive Summary
Cardiac surgical device maker gains 510(k) clearance Oct. 23 for its ATS Simulus semi-rigid annuloplasty ring for mitral valve repair. The device was developed and marketed through a partnership with Genesee BioMedical. ATS estimates the market for valve repair devices at $100 million, with about 50% of procedures using semi-rigid devices. "The ease and reproducibility facilitated during implant" of our Simulus flexible rings and bands "has helped us rapidly carve out a significant niche within the minimally invasive and robotic valve market; one that we look to build upon and exceed with our semi-rigid product," said CEO Michael Dale. ATS awaits U.S. approval of its first tissue valve, the ATS 3F aortic bioprosthesis, and its AP360 mechanical heart valve
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.